Back to search
Search Results 1-10 of 14 clinical trials found.
Background: Allergic reactions have been reported to occur after vaccination with both the
Pfizer-BioNTech COVID-19 Vaccine and Moderna COVID-19 Vaccine. Allergic reactions range from
mild to severe and include life- threatening anaphylactic reactions, although no deaths have
been reported with either vaccine.
This study is designed with two principal aims:
- To estimate the proportions of systemic allergic reactions to the Pfizer-BioNTech
COVID-19 Vaccine and the Moderna COVID-19 Vaccine in a High-Allergy/Mast Cell Disorder
(HA/MCD) population, and
- If the risk in the HA/MCD is demonstrable, to determine whether the proportions are
higher in the HA/MCD compared to a non-atopic population.
ACTIV-1 IM is a master protocol designed to evaluate multiple investigational agents for the
treatment of moderately or severely ill patients infected with severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2). The research objectives are to evaluate each agent with
respect to speed of recovery, mortality, illness severity, and hospital resource utilization.
Each agent will be evaluated as add-on therapy to the standard of care (SoC) in use at the
local clinics, including remdesivir (provided). The SoC may change during the course of the
study based on other research findings. Comparisons of the agents among themselves is not a
The study population corresponds to moderately and severely ill patients infected with the
coronavirus disease 2019 (COVID-19) virus. Recruitment will target patients already
hospitalized for treatment of COVID-19 infection as well as patients being treated for
This is a randomized, open label, adaptive platform trial to compare the effectiveness of
antithrombotic strategies for prevention of adverse outcomes in COVID-19 positive inpatients
New agents are becoming available that may be useful for the treatment of non-hospitalized persons with COVID-19. ACTIV-2 is an NIH-sponsored phase II/III randomized, blinded, controlled adaptive platform trial to assess various investigational agents that have shown substantial promise as anti-SARS-CoV-2 therapeutics in pre-clinical and phase I testing. The study is designed to allow both phase II and phase III evaluation of promising investigational agents against placebo in a single trial.
Back to search
Learn more about myUCLAhealth